Cancer

DiMe launches new initiative to scale trusted, high-impact AI care navigation in response to how patients are already using AI to navigate care

Founding members span Big Tech, healthcare, payers, and patient groups to define what good looks like for trusted AI-enabled care…

1 month ago

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical…

1 month ago

Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology

CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ -- Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and…

1 month ago

Electrome Corporation Launches LymeCure™ Research Study

Electrome Bioelectric Therapeutics Platform being used to explore inhibition of pathogen motility and persistence, with implications for infectious disease, pharma,…

1 month ago

DR. ANDREW WEIL AND DAUGHTER DIANA WEIL UPDATE ANTI-INFLAMMATORY FOOD PYRAMID FOR 2026 AFTER 20 YEARS

The refreshed Dr. Weil's Anti-Inflammatory Food Pyramid™ modernizes one of the best-ranked diets by U.S. News & World Report and…

1 month ago

Verana Health Merges with COTA to Dramatically Expand Scale, Velocity, and Depth of Real-World Data Offerings Across Oncology and Other Specialties

Combined teams and proprietary AI-technology to multiply capabilities and services as a leading provider of real-world data for clinical researchSAN…

1 month ago

Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award

Tony Hunter, Ph.D., celebrated for pioneering discoveries that inspired the development of more than 80 cancer therapies that continue to…

1 month ago

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of…

1 month ago

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences…

1 month ago

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy…

1 month ago